Señales en vivo de XINT.ST | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 may 2024 @ 11:29):

Stats
Volumen de hoy	113 931
Volumen promedio	251 321
Capitalización de mercado	161.60M
EPS	SEK-0.0265 ( 2023-09-30 )
Próxima fecha de ganancias	( SEK0 ) 2024-05-08
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-2.19
ATR14	SEK0.00600 (2.11%)

Xintela AB (publ) Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Xintela AB (publ) Finanzas

Annual	2023
Ingresos:	SEK78 000.00
Beneficio Bruto:	SEK-3.69M (-4 728.21 %)
EPS:	SEK-0.130

FY	2023
Ingresos:	SEK78 000.00
Beneficio Bruto:	SEK-3.69M (-4 728.21 %)
EPS:	SEK-0.130

FY	2022
Ingresos:	SEK0
Beneficio Bruto:	SEK-3.79M (0.00 %)
EPS:	SEK-0.370

FY	2021
Ingresos:	SEK0.00
Beneficio Bruto:	SEK0.00 (0.00 %)
EPS:	SEK-0.557

Financial Reports:

No articles found.

Xintela AB (publ)

Xintela AB (publ), a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage and brain tumors. The company develops products based on XINMARK, a patented marker technology that identifies and selects a range of stem cells, which can develop cartilage cells. It is also developing XSTEM a stem cell product that is in clinical development phase for the treatment of knee osteoarthritis and difficult-to-heal leg ulcers; and EQSTEM, a stem cell product for the treatment of joint diseases in horses, as well as focuses on the preclinical development of therapeutic antibodies for aggressive cancers, including brain tumor glioblastoma and triple negative breast cancer. Xintela AB (publ) was founded in 2009 and is based in Lund, Sweden.

Actualizaciones en tiempo real para Xintela AB (publ) [XINT.ST]

Upcoming Earnings Alert